Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May;133(5):1369-72.
doi: 10.1038/jid.2012.501. Epub 2013 Jan 10.

Association of generalized vitiligo with MHC class II loci in patients from the Indian subcontinent

Stanca A Birlea, Fridoon J Ahmad, Raza M Uddin, Shakil Ahmad, Sabrina S Pal, Rasheedunnisa Begum, Naresh C Laddha, Mitesh Dwivedi, Mohmmad Shoab Mansuri, Ying Jin, Katherine Gowan, Sheri L Riccardi, Paulene J Holland, Songtao Ben, Pamela R Fain, Richard A Spritz

Association of generalized vitiligo with MHC class II loci in patients from the Indian subcontinent

Stanca A Birlea et al. J Invest Dermatol. 2013 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The authors state no conflict of interest.

Figures

Figure 1
Figure 1. Immunochip association results for generalized vitiligo
(a) The distribution of −log10(P-values) from the Cochran-Armitage trend test is shown plotted across the chromosomes for 120,274 SNPs that passed quality control filters in 251 cases and 349 controls. The dashed blue line indicates the genome-wide significance criterion (P<5 × 10−8) that has been agreed for studies utilizing the Immunochip (Cortes and Brown, 2011). (b) A genomic map of the extended MHC, including class I and class II region of association, with the positions of rs3096691, rs3129859, and rs482044 indicated. (c) Pattern of LD (D’) observed across the MHC class II region of association.
Figure 1
Figure 1. Immunochip association results for generalized vitiligo
(a) The distribution of −log10(P-values) from the Cochran-Armitage trend test is shown plotted across the chromosomes for 120,274 SNPs that passed quality control filters in 251 cases and 349 controls. The dashed blue line indicates the genome-wide significance criterion (P<5 × 10−8) that has been agreed for studies utilizing the Immunochip (Cortes and Brown, 2011). (b) A genomic map of the extended MHC, including class I and class II region of association, with the positions of rs3096691, rs3129859, and rs482044 indicated. (c) Pattern of LD (D’) observed across the MHC class II region of association.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cortes A, Brown MA. Promise and pitfalls of the Immunochip. Arthritis Res Ther. 2011;13:101. - PMC - PubMed
    1. Das SK, Majumder PP, Chakraborty R, Majumdar TK, Haldar B. Studies on vitiligo. I. Epidemiological profile in Calcutta, India. Genet Epidemiol. 1985;2:71–78. - PubMed
    1. Handa S, Kaur I. Vitiligo: clinical findings in 1436 patients. J Dermatol. 1999;26:653–657. - PubMed
    1. Jin Y, Birlea SA, Fain PR, Gowan K, Riccardi SL, Holland PJ, Mailloux CM, Sufit AJ, Hutton SM, Amadi-Myers A, Bennett DC, Wallace MR, McCormack WT, Kemp EH, Gawkrodger DJ, Weetman AP, Picardo M, Leone G, Taieb A, Jouary T, Ezzedine K, van GN, Lambert J, Overbeck A, Spritz RA. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med. 2010;362:1686–1697. - PMC - PubMed
    1. Jin Y, Birlea SA, Fain PR, Gowan K, Riccardi SL, Holland PJ, Bennett DC, Herbstman DM, Wallace MR, McCormack WT, Kemp EH, Gawkridger DJ, Weetman AP, Picardo M, Leone G, Taieb A, Jouray T, Ezzedine K, van Geel N, Lambert J, Overbeck A, Spritz RA. Genome-wide analysis identifies a quantitative trait locus in the MHC class II region associated with generalized vitiligo age of onset. J Invest Dermatol. 2011;131:1308–1312. - PMC - PubMed

Publication types